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Angiotensin in ECMO patients with
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Refractory vasodilation and catecholamine resistance
are common in septic shock. Changes in receptor
signaling, excessive production of nitric oxide, and
absolute or relative deficiencies of vasoactive
hormones, including cortisol, vasopressin, and angio-
tensin II, play a role. Angiotensin II (Ang II) was
previously available as a vasopressor but removed
from the market in the 1990s. Interest was re-ignited
following the Angiotensin II for the Treatment of
Vasodilatory Shock (ATHOS-3) study, a randomized
controlled trial in patients with refractory shock
which confirmed that Ang II was effective at main-
taining mean arterial pressure and reducing norepin-
ephrine requirements without an increase in side
effects [1]. Patients receiving renal replacement ther-
apy also had improved survival and faster recovery of
renal function [2]. Recent literature noted the poten-
tial role of Ang II in other types of shock [3].
The major physiological effects of Ang II relate to
maintenance of hemodynamic stability and fluid and
electrolyte regulation (Table 1). Angiotensinogen, the
precursor of angiotensin, is produced primarily by the
liver and released into the systemic circulation where
it is converted to angiotensin I (Ang I). Ang I is
cleaved into Ang II, predominantly by angiotensin
converting enzyme (ACE), an endothelium bound
protein that is primarily expressed in the pulmonary
and renal capillary beds. In patients with acute res-
piratory distress syndrome, ACE insufficiency has
been reported [4]. In veno-arterial ECMO, a propor-
tion of blood bypasses the lungs, which further limits
the conversion of Ang I to Ang II. Other conditions
associated with reduced Ang II levels include Gram-
negative sepsis where endotoxinemia can deactivate
ACE. Importantly, low levels of Ang II and ACE are
associated with increased mortality [5].
We report the successful management of seven
patients (four male; mean age 36 years) with severe
cardiorespiratory failure and refractory shock
treated with extracorporeal membrane oxygenation
(ECMO) who received Ang II in the context of the
ATHOS-3 trial [1] or a compassionate use program
(Table 2). Following initiation of Ang II, a profound
effect on blood pressure was seen and the doses of
vasopressors were reduced quickly. Time to cessa-
tion of vasopressors and catecholamines ranged
from 16 h to 8 days. Six patients were discharged
home alive.
In conclusion, in patients with severe cardio-respira-
tory failure requiring ECMO, treatment with Ang II in
addition to standard supportive care enabled rapid decate-
cholaminization. Underlying ACE deficiency may be a
contributing factor. Further studies are necessary to con-
firm the findings.
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Table 2 Patient characteristics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age (years) 23 26 41 48 38 50 37
Gender M M F F M F M
Primary acute illness Influenza A infection Sepsis Influenza B and MRSA
pneumonia
Sepsis post
acute MI
Aspiration pneumonia Pulmonary embolism Type A
aortic dissection
Secondary acute
illness
Cardiac arrest due to
pericardial effusion
Cardiac arrest Sepsis and cardiogenic
shock
Drug overdose (calcium
channel blocker and
beta blocker)
Multi-organ failure Poly-microbial
sepsis
Confounding factors None Idiopathic dysautonomy
and mast cell activation
syndrome
Obesity HIV positive Obesity Recent craniotomy
for meningioma
Large RV and
LV infarct
Type of ECMO VA ECMO VA ECMO VA ECMO VV ECMO VV ECMO VA ECMO VA ECMO
Vasopressor support
*pre-Ang II
administration
Norepinephrine 0.4
Vasopressin 4
Epinephrine 0.07
Norepinephrine 1
Vasopressin 6
Epinephrine 0.3
Epinephrine 0.18
Vasopressin 2
Norepinephrine
0.59
Norepinephrine 1.36
Vasopressin 2.4
Norepinephrine 0.2
Vasopressin 5
Milrinone 0.25
Epinephrine 0.05
Norepinephrine 0.1
Vasopressin 4
Epinephrine 0.02
MAP at initiation of
Ang II [mmHg]
Missing 57 76 70 63 59 59
Dose of Ang II
[ng/kg/min]
Missing Missing 20 20 40 20 20
Duration of Ang II 7 days 46 h 50 h 27.5 h 80 h
Time to cessation of
all vasopressors after
initiation of Ang II
Missing 48 h Missing 16 h 6 days 8 days NA
Adverse events
during Ang II
infusion
None None Reversible digital
ischemia
None None None Bowel ischemia
Patient outcome Survival Survival Survival Survival Survival Survival Deceased
Duration on ECMO
[days]
17 5 119 4 9 9 14
Length of stay in
ICU [days]
176 30 128 21 22 13 14
Abbreviations: Ang II angiotensin II, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, LV left ventricle, MAPmean arterial pressure,MRSAmethicillin-resistant staphylococcus
aureus, RV right ventricle, VA veno-arterial, VV veno-venous
*Units of drugs: norepinephrine in μg/kg/min; epinephrine in μg/kg/min; vasopressin in units/h; milrinone in μg/kg/min
Table 1 Main physiological effects of angiotensin II
Organ system Physiological effects
Vascular ● Vasoconstriction of venous and arterial vessels
● Increased vascular permeability
Renal ● Stimulation of Na reabsorption and H+ excretion in the proximal tubule via Na+/H+ exchanger
● Stimulation of the release of aldosterone
● Variable effects on glomerular filtration and renal blood flow depending on the physiological and
pharmacological setting:
➢ constriction of the afferent and efferent glomerular arterioles with greater effect on the efferent vessel
➢ constriction of the glomerular mesangium
➢ enhanced sensitivity to tubulo-glomerular feedback
➢ increased local release of prostaglandins which antagonize renal vasoconstriction
Endocrine ● Stimulation of the secretion of vasopressin from the posterior pituitary gland
● Secretion of ACTH
● Enhanced release of noradrenaline from postganglionic sympathetic fibers
Nervous ● Enhancement of noradrenaline secretion
Cardiac ● Mediation of cardiac remodeling through activated tissue RAS in cardiac myocytes
Coagulation ● Prothrombotic potential
Immune ● Promotion of cell growth and inflammation
● Increased expression of endothelium-derived adhesion molecules
● Synthesis of pro-inflammatory cytokines and chemokines
● Generation of reactive oxygen species
Abbreviations: ACTH adrenocorticotropin hormone, Ang II angiotensin II, GFR glomerular filtration rate, RAS renin-angiotensin system
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Abbreviations
ACE: Angiotensin converting enzyme; Ang I: Angiotensin I; Ang
II: Angiotensin II; ATHOS: Angiotensin II for the Treatment of Vasodilatory
Shock; ECMO: Extracorporeal membrane oxygenation
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